Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18211709 | 0.85 | MEN1 (0.39) | MEN1KMT2ACA2CA9ALOX5 | |
| SCHEMBL16353940 | 0.83 | MEN1 (0.41) | MEN1KMT2APOLBGAANPSR1 | |
| SCHEMBL19105219 | 0.83 | MEN1 (0.38) | MEN1KMT2ACA2CA9ALOX5 | |
| SCHEMBL17523106 | 0.82 | MEN1 (0.37) | MEN1KMT2APRKCACA2CA9 | |
| SCHEMBL8247883 | 0.78 | MEN1 (0.46) | MEN1KMT2APOLBGAANPSR1 | |
| SCHEMBL4258156 | 0.78 | POLB (0.48) | MEN1KMT2APOLBGAANPSR1 | |
| SCHEMBL2478567 | 0.77 | NPC1 (0.41) | POLBGAANPSR1PRKCACA2 | |
| SCHEMBL28586646 | 0.77 | MEN1 (0.44) | MEN1KMT2APOLBGAANPSR1 | |
| SCHEMBL19105278 | 0.76 | MEN1 (0.36) | MEN1KMT2ACA2CA9ALOX5 | |
| SCHEMBL16176156 | 0.76 | MEN1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174988-B2 | Small molecule inhibitors of hepatitis C virus | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130065875-A1 | SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329742-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329742-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915306-B2 | For therapy of inflammatory or autoimmune disorders | EISAI CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-5977394-A | Silyl thioalkene compound and method for the preparation thereof | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144101-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT1, TBXA2R, VEGFA | MEN1 169/4885KMT2A 4194/4885POLB 2548/4885 |
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT4, VEGFA, FLT1 | MEN1 737/4885KMT2A 4207/4885POLB 2699/4885 |
| US-20130065875-A1 | SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, LIPC | MEN1 4699/4885KMT2A 3932/4885POLB 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.